The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Size Of The Primary Ovarian Insufficiency Market Progress Through 2030?
The primary ovarian insufficiency market has seen robust growth in recent years. It is anticipated to expand from $1.18 billion in 2025 to $1.3 billion in 2026, at a compound annual growth rate (CAGR) of 10.0%. This historical expansion can be attributed to factors like heightened awareness of female reproductive health, increased utilization of hormone replacement therapy, a surge in demand for infertility treatments, enhanced diagnostic abilities for hormonal disorders, and the growth of specialty fertility clinics.
The primary ovarian insufficiency market is poised for significant expansion in the coming years. It is forecast to achieve a valuation of $1.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period is propelled by factors such as increasing investment in regenerative medicine research, an escalating demand for early diagnosis solutions, the widespread adoption of precision medicine approaches, a heightened focus on non-invasive fertility treatments, and the growing availability of advanced reproductive technologies. Key developments expected during this period include the increasing uptake of personalized hormone therapies, a rise in the application of advanced diagnostic testing, a stronger emphasis on fertility preservation solutions, the expansion of regenerative and stem cell-based treatments, and the improved integration of multidisciplinary care models.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24387&type=smp
Which Significant Factors Are Encouraging Growth In The Primary Ovarian Insufficiency Market?
The growing incidence of autoimmune conditions is projected to drive the expansion of the primary ovarian insufficiency market in the future. Autoimmune disorders are conditions where the immune system incorrectly targets and harms the body’s own healthy cells and tissues. The rising occurrence of these disorders is largely attributed to genetic factors, where individuals inherit specific genes that increase their vulnerability to immune system dysfunctions. Primary ovarian insufficiency (POI) offers insights into autoimmune disorders by illustrating the interplay between hormonal imbalances and immune system dysregulation, which contributes to a greater likelihood of autoimmune diseases in those affected. For instance, by 2025, as per WeCovr, an UK-based embedded insurance platform, it is predicted that more than 3.5 million people in the UK will be afflicted with an autoimmune disease, representing an increase of almost 40% since the early 2000s, which is higher than previous estimations of 3% to 9%. Consequently, the rising prevalence of autoimmune disorders is a key factor boosting the primary ovarian insufficiency market.
Which Segment Divisions Form The Structure Of The Primary Ovarian Insufficiency Market?
The primary ovarian insufficiency market covered in this report is segmented –
1) By Type: Hormone Replacement Therapy (HRT), Calcium and Vitamin D Supplements, In Vitro Fertilization (IVF), Stem Cell Therapy, Other Types
2) By Diagnosis Method: Blood Tests, Ultrasound Imaging, Genetic Testing
3) By Application: Less Than 20 Years Old, 20 To 30 Years Old, 30 To 45 Years Old, Perimenopausal Age Group Exclusion As POI Occurs Before 40
4) By End-Users: Hospitals And Clinics, Specialty Fertility Centers
Subsegments:
1) By Hormone Replacement Therapy: Estrogen Therapy, Estrogen-Progestin Therapy, Transdermal Patches, Vaginal Estrogen Products, Oral Hormone Therapy
2) By Calcium And Vitamin D Supplements: Calcium Carbonate, Calcium Citrate, Vitamin D2 (Ergocalciferol), Vitamin D3 (Cholecalciferol), Combined Calcium + Vitamin D Formulations
3) By In Vitro Fertilization: Conventional In Vitro Fertilization, Intracytoplasmic Sperm Injection (ICSI), Egg Donation In Vitro Fertilization, Embryo Freezing And Transfer, Preimplantation Genetic Testing (PGT)
4) By Stem Cell Therapy: Autologous Stem Cell Therapy, Allogeneic Stem Cell Therapy, Mesenchymal Stem Cell (MSC) Therapy, Ovarian Stem Cell Transplantation
5) By Other Types: Psychological Counseling And Support Therapies, Assisted Reproductive Technologies (other than IVF), Immunomodulatory Therapies, Lifestyle And Dietary Interventions
Key companies within the primary immunodeficiency disorders market are concentrating on developing advanced therapies, such as intravenous immunoglobulin therapy, to improve patient outcomes by enhancing immune function. Intravenous immunoglobulin (IVIG) therapy involves administering immunoglobulin (antibodies) sourced from donor plasma directly into a patient’s bloodstream via an IV. For example, in June 2024, Grifols, a Spain-based healthcare company, obtained FDA approval for Yimmugo, an intravenous immunoglobulin (IVIg) therapy. This newly developed, sugar-free, ready-to-use IgG solution originates from human blood plasma and is intended for intravenous delivery. Approved in the U.S. for substitution therapy in patients with primary antibody deficiency syndromes, Yimmugo provides antibody replacement to support individuals with immune system deficiencies. It thereby expands Grifols’ portfolio of plasma-based treatments by offering a safer and more effective choice to assist in protection against infections.
Who Are The Key Market Participants In The Primary Ovarian Insufficiency Market?
Major companies operating in the primary ovarian insufficiency market are Mayo Clinic, Johns Hopkins Medicine, Baptist Health, Ferring Pharmaceuticals AS, PreventionGenetics LLC, The Fertility Partnership UK, Celmatix Inc, IVIRMA Global, Bioscience Institute SpA, Sparsh Diagnostics Pvt Ltd, Bristol Menopause Clinic, Indira IVF Hospital Private Limited, Lawley Pharmaceuticals Pty Ltd, OvaScience Inc, Merck KGaA, Roche Holding AG, Pfizer Inc, Novartis AG, AbbVie Inc, Eli Lilly And Company, Bayer AG, Takeda Pharmaceutical Company Limited
Access The Complete Primary Ovarian Insufficiency Market Report:
https://www.thebusinessresearchcompany.com/report/primary-ovarian-insufficiency-global-market-report
Which Region Accounts For The Highest Share Of The Primary Ovarian Insufficiency Market?
North America was the largest region in the primary ovarian insufficiency market in 2025. The regions covered in the primary ovarian insufficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Primary Ovarian Insufficiency Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=24387&type=smp
Browse Through More Reports Similar to the Global Primary Ovarian Insufficiency Market 2026, By The Business Research Company
Immunoassay Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report
Acne Drugs Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report
Immunodiagnostics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunodiagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
